Abstract 2312
Background
MicroRNAs (miRs) are small non-coding RNAs. Circulating miRs in plasma are deregulated in patients with metastatic colorectal cancer (mCRC). The aim was to find prognostic circulating miRs for overall survival (OS) in patients with mCRC treated with chemotherapy and cetuximab.
Methods
A prospective biomarker study was conducted. A full plasma miR-panel was tested with TaqMan Human MicroRNA assay in 151 patients treated with 3rd line irinotecan and cetuximab (Discovery cohort, Biweekly study). Significant miRs were validated with Fluidigm arrays, in 95 patients, treated with 1st line chemotherapy and cetuximab (Validation cohort, NORDIC-7.5 study1). Cox regression analysis was conducted, and multivariate analyses performed with adjustment for sidedness, number of metastatic sites, RAS/BRAF mutation status, age and performance status. Consecutive samples after 3 months of treatment were available for 117 and 86 patients in the discovery and validation cohorts, respectively.
Results
Baseline high expression of miR-1247 in the discovery and validation cohorts, was significantly associated with short OS (hazard ratio [HR]) = 2.33, p = 0.0005) based on the multivariate analysis in the validation cohort. High miR-1290 expression after 3 months was prognostic for short progression free-survival (HR = 1.57, p = 0.0465) in both cohorts. In both cohorts, we found a statistically significant decrease in, miR-1290 (p = 0.0051), miR-200b (p = 0.036), and miR-375 (p = 0.00005), from baseline to 3 month-sample, in patients with partial/complete (n = 78) response compared to patients with progressive disease (n = 72).
Conclusions
High expression of miR-1247 was prognostic for short OS in the multivariate analysis in a discovery and validation cohort of patients treated with chemotherapy and cetuximab in both first and third line. A decrease in miR-1247 and miR-1290 during treatment was associated with favorable response. 1Pfeiffer et al, Clin Colorectal Cancer 2015.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jakob Vasehus Scho.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3180 - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.
Presenter: Lunda Gu
Session: Poster Display session 2
Resources:
Abstract
4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis
Presenter: Masayuki Ueno
Session: Poster Display session 2
Resources:
Abstract
3203 - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.
Presenter: Anne Demols
Session: Poster Display session 2
Resources:
Abstract
1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2848 - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
1396 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1139 - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Presenter: Andrea Casadei-gardini
Session: Poster Display session 2
Resources:
Abstract
4688 - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Tim Meyer
Session: Poster Display session 2
Resources:
Abstract
1492 - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
Presenter: David Pinato
Session: Poster Display session 2
Resources:
Abstract
3159 - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study
Presenter: AiPing Zhou
Session: Poster Display session 2
Resources:
Abstract